Table 1.
Characteristics of the study population concerning the concomitant presence of hepatic steatosis.
| Variable | Hepatic Steatosis | p-Value | ||
|---|---|---|---|---|
| Yes (n = 193) | No (n = 214) | Total (n = 407) | ||
| Age, years (median, range) | 69 (36–89) | 67.5 (34–86) | 68 (34–89) | 0.166 |
| Sex, male (n, %) | 101 (52.33) | 118 (55.14) | 219 (53.81) | 0.570 |
| Fasting glucose, mmol/L (median, range) | 6.1 (2.4–15.9) | 5.45 (2.8–16.7) | 5.9 (2.4–16.7) | <0.001 |
| Systolic blood pressure, mmHg (median, range) | 140 (80–240) | 140 (85–230) | 140 (80–240) | 0.036 |
| Diastolic blood pressure, mmHg (median, range) | 90 (60–145) | 90 (45–145) | 90 (45–145) | 0.293 |
| Tryglicerides, mmol/L (median, range) | 1.96 (0.5–6.67) | 1.7 (0.2–13) | 1.8 (0.2–13) | <0.001 |
| HDL 1 cholesterol, mmol/L (median, range) | 1 (0.3–2.46) | 1.02 (0.2–2.3) | 1 (0.2–2.46) | 0.093 |
| Total cholesterol, mmol/L (median, range) | 5.7 (1.18–9.8) | 4.8 (1.45–10) | 5.03 (1.18–10) | <0.001 |
| CRP 2, mg/L (median, range) | 12 (0.1–418.5) | 5 (0.1–211) | 8 (0.1–418.5) | <0.001 |
| Hypertension (yes/no, n (%)) | 149/44 (77.2/22.8) | 114/100 (53.27/46.73) | 263/144 (64.62/35.38) | <0.001 |
| Diabetes mellitus type 2 (yes/no, n (%)) | 126/67 (65.28/34.72) | 95/119 (44.39/55.61) | 221/186 (54.3/45.7) | <0.001 |
| Hypothyroidism (yes/no, n (%)) | 41/152 (21.24/78.76) | 24/190 (11.21/88.79) | 65/342 (15.97/84.03) | 0.008 |
| AST 3, U/L (median, range) | 18 (8–187) | 15 (6–676) | 16 (6–676) | <0.001 |
| ALT 4, U/L (median, range) | 18 (6–364) | 15 (7–259) | 17 (6–364) | 0.001 |
| ALP 5, U/L (median, range) | 35 (9–401) | 18 (9–703) | 24 (9–703) | <0.001 |
| GGT 6, U/L (median, range) | 26 (5–735) | 20 (8–1115) | 23 (5–1115) | 0.011 |
| Chronic kidney disease, unspecified (yes/no, n (%)) | 9/184 (4.66/95.34) | 4/210 (1.87/98.13) | 13/394 (3.19/96.81) | 0.187 |
1 High-density lipoprotein,2 C-reactive protein, 3 Aspartate amino-transferase, 4 Alanin amino-transferase, 5 Alkaline phosphatase, 6 Gamma glutamyl transferase.